scholarly journals Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy

Oncotarget ◽  
2017 ◽  
Vol 8 (35) ◽  
pp. 58108-58121 ◽  
Author(s):  
Mary Jo Fidler ◽  
Casey Frankenberger ◽  
Richard Seto ◽  
Gabriela C. Lobato ◽  
Cristina L. Fhied ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cytotoxic Chemotherapy ◽  
Small Cell ◽  
Circulating Biomarkers ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Tumor Phenotype ◽  
Previously Treated

scholarly journals Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients

2019 ◽  
Vol 10 (4) ◽  
pp. 775-781 ◽  
Author(s):  
Ayako Shiono ◽  
Kyoichi Kaira ◽  
Atsuto Mouri ◽  
Ou Yamaguchi ◽  
Kosuke Hashimoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Previously Treated

Assessment of PD-L1 expression and oncogenic gene status in patients with small-cell lung cancer: Immuno-oncology biomarker study in LC-SCRUM-Japan.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 8558-8558
Author(s):  
Satoshi Oizumi ◽  
Kiyotaka Yoh ◽  
Shingo Matsumoto ◽  
Shingo Miyamoto ◽  
Naoki Furuya ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Cytotoxic Chemotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Gene Status ◽  
Oncogenic Gene

8558 Background: The clinical impact of PD-L1 expression and oncogenic gene status in patients with small cell lung cancer (SCLC) is not well characterized. We initiated this immuno-oncology biomarker study as part of nationwide genomic screening by LC-SCRUM-Japan (LC-SCRUM-IBIS). Methods: Tumor samples from lung cancer patients enrolled in LC-SCRUM-IBIS were primarily subjected to targeted next-generation sequencing (NGS) with Oncomine™ Comprehensive Assay. The PD-L1 expression was also analyzed by 4 immunohistochemistry (IHC) assays for 22C3, 28-8, SP263 and SP142. At this analysis, 22C3, 28-8, and SP263 were assessed in tumor cells (TC) as positive in > 1%, and SP142 in both TC and tumor-infiltrating immune cells (IC) as positive in > TC1/IC1, as previously reported. The association of PD-L1 expression, oncogenic gene status and clinical outcome was investigated in SCLC patients. Results: Between Feb 2017 and May 2018, 1017 lung cancer patients were enrolled in LC-SCRUM-IBIS. Among them, 933 patients had adequate tumor samples including 101 SCLC and 832 non-small cell lung cancer. Of 101 SCLC patients, the results of PD-L1 expression by 4 IHC assays were 18% in 22C3, 17% in 28-8, 11% in SP263 and 8% in SP142, respectively. Targeted NGS showed that 8 patients had at least one targetable oncogenic alterations, including 3 PIK3CA and 1 KRAS as mutations and 3 PTEN and 1 TSC2 as inactivating mutations. PD-L1 expression by 22C3 was associated with good performance status (P = 0.05) and the presence of oncogenic alterations (P = 0.004). PD-L1 status was not associated with response to cytotoxic chemotherapy and progression-free survival and overall survival in first-line treatment of SCLC patients. Conclusions: The frequency of PD-L1 expression in SCLC patients was relatively lower compared with that reported in other solid tumors. PD-L1 status by TC in 22C3 appears to be not correlated with clinical outcomes for cytotoxic chemotherapy of SCLC patients. Further investigation is needed to explore a predictive biomarker for immune checkpoint inhibitors. Updated results will be presented at the meeting.

scholarly journals Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy

2020 ◽  
Vol 10 ◽  
Author(s):  
Feliciano Barrón ◽  
Roberto Sánchez ◽  
Marisol Arroyo-Hernández ◽  
Carolina Blanco ◽  
Zyanya L. Zatarain-Barrón ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Previously Treated

Atezolizumab in previously treated non-small-cell lung cancer patients

2021 ◽  
Author(s):  
Mariana Serino ◽  
Vanessa Santos ◽  
David Araújo ◽  
Hélder Novais-Bastos ◽  
Adriana Magalhães ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Previously Treated
Sign in / Sign up

Export Citation Format

Share Document